Eisai Inc., of Woodcliff Lake, N.J., said it started a randomized phase III study that will evaluate the efficacy and safety of two regimens containing Eisai's multiple receptor tyrosine kinase inhibitor lenvatinib, marketed in the U.S. as Lenvima. One combination will add lenvatinib to anti-PD-1 immunotherapy Keytruda (pembrolizumab, Merck & Co. Inc.) and the other will test lenvatinib in combination with everolimus, both vs. Sutent (sunitinib, Pfizer Inc.), in patients with advanced renal cell carcinoma in the first-line setting. The CLEAR study is designed to assess the potential of those combinations to extend progression-free survival.